SEK 1.64
(-1.2%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | - SEK | 0.0% |
2022 | - SEK | 0.0% |
2021 | - SEK | -100.0% |
2020 | 83 Thousand SEK | -95.24% |
2019 | 1.74 Million SEK | -90.22% |
2018 | 17.84 Million SEK | 583.64% |
2017 | 2.61 Million SEK | -15.34% |
2016 | 3.08 Million SEK | -54.47% |
2015 | 6.77 Million SEK | 43.57% |
2014 | 4.71 Million SEK | 0.0% |
2013 | - SEK | -100.0% |
2012 | 6.68 Million SEK | 378.53% |
2011 | 1.39 Million SEK | 110.08% |
2010 | 665 Thousand SEK | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - SEK | 0.0% |
2023 Q3 | - SEK | -100.0% |
2023 FY | - SEK | 0.0% |
2023 Q1 | 6.11 Million SEK | 0.0% |
2023 Q4 | - SEK | 0.0% |
2023 Q2 | 154 Thousand SEK | -97.48% |
2022 Q1 | 2.73 Million SEK | 0.0% |
2022 Q2 | - SEK | -100.0% |
2022 FY | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 Q4 | - SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2021 Q4 | - SEK | 0.0% |
2021 FY | - SEK | -100.0% |
2021 Q1 | - SEK | -100.0% |
2021 Q2 | - SEK | 0.0% |
2020 Q2 | 583 Thousand SEK | -66.59% |
2020 FY | 83 Thousand SEK | -95.24% |
2020 Q1 | 1.74 Million SEK | 0.0% |
2020 Q4 | 83 Thousand SEK | -75.15% |
2020 Q3 | 334 Thousand SEK | -42.71% |
2019 Q3 | 1.82 Million SEK | -24.2% |
2019 FY | 1.74 Million SEK | -90.22% |
2019 Q4 | 1.74 Million SEK | -4.59% |
2019 Q2 | 2.41 Million SEK | -19.51% |
2019 Q1 | 2.99 Million SEK | -83.2% |
2018 Q1 | 2.2 Million SEK | -15.44% |
2018 FY | 17.84 Million SEK | 583.64% |
2018 Q4 | 17.84 Million SEK | 54.97% |
2018 Q3 | 11.51 Million SEK | 29.05% |
2018 Q2 | 8.92 Million SEK | 304.26% |
2017 Q1 | 2.83 Million SEK | -8.11% |
2017 Q4 | 2.61 Million SEK | 11.87% |
2017 Q3 | 2.33 Million SEK | -9.68% |
2017 Q2 | 2.58 Million SEK | -8.82% |
2017 FY | 2.61 Million SEK | -15.34% |
2016 Q4 | 3.08 Million SEK | -7.5% |
2016 Q2 | 3.58 Million SEK | -66.88% |
2016 Q3 | 3.33 Million SEK | -6.98% |
2016 Q1 | 10.81 Million SEK | 59.73% |
2016 FY | 3.08 Million SEK | -54.47% |
2015 Q2 | 4 Million SEK | 60.0% |
2015 Q4 | 6.77 Million SEK | 69.3% |
2015 Q3 | 4 Million SEK | 0.0% |
2015 FY | 6.77 Million SEK | 43.57% |
2015 Q1 | 2.5 Million SEK | -47.0% |
2014 FY | 4.71 Million SEK | 0.0% |
2014 Q3 | 2.15 Million SEK | 0.0% |
2014 Q2 | - SEK | 0.0% |
2014 Q1 | - SEK | 0.0% |
2014 Q4 | 4.71 Million SEK | 118.99% |
2013 Q4 | - SEK | -100.0% |
2013 FY | - SEK | -100.0% |
2013 Q1 | - SEK | -100.0% |
2013 Q3 | 7.29 Million SEK | 0.0% |
2012 Q4 | 6.68 Million SEK | 0.0% |
2012 FY | 6.68 Million SEK | 378.53% |
2011 FY | 1.39 Million SEK | 110.08% |
2010 FY | 665 Thousand SEK | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Acarix AB (publ) | - SEK | NaN% |
ADDvise Group AB (publ) | 1.61 Billion SEK | 100.0% |
ADDvise Group AB (publ) | 1.61 Billion SEK | 100.0% |
Arcoma AB | 3.87 Million SEK | 100.0% |
Bactiguard Holding AB (publ) | 233.09 Million SEK | 100.0% |
BICO Group AB (publ) | 1.85 Billion SEK | 100.0% |
Boule Diagnostics AB (publ) | 166.1 Million SEK | 100.0% |
CellaVision AB (publ) | 64.7 Million SEK | 100.0% |
Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | 100.0% |
Chordate Medical Holding AB (publ) | - SEK | NaN% |
C-Rad AB (publ) | 1.8 Million SEK | 100.0% |
Duearity AB (publ) | 10.58 Million SEK | 100.0% |
Dignitana AB (publ) | 19.1 Million SEK | 100.0% |
Episurf Medical AB (publ) | 5.2 Million SEK | 100.0% |
Getinge AB (publ) | 8.07 Billion SEK | 100.0% |
Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 100.0% |
Iconovo AB (publ) | 7.72 Million SEK | 100.0% |
Integrum AB (publ) | 6.42 Million SEK | 100.0% |
Luxbright AB (publ) | 206.02 Thousand SEK | 100.0% |
Mentice AB (publ) | 9.55 Million SEK | 100.0% |
OssDsign AB (publ) | 3.15 Million SEK | 100.0% |
Paxman AB (publ) | 13.57 Million SEK | 100.0% |
Promimic AB (publ) | - SEK | NaN% |
Qlife Holding AB (publ) | 20.73 Million SEK | 100.0% |
SciBase Holding AB (publ) | 6.79 Million SEK | 100.0% |
Sectra AB (publ) | 31.78 Million SEK | 100.0% |
Sedana Medical AB (publ) | 4.3 Million SEK | 100.0% |
Senzime AB (publ) | 11.46 Million SEK | 100.0% |
SpectraCure AB (publ) | 6.71 Million SEK | 100.0% |
Stille AB | 62.94 Million SEK | 100.0% |
Vitrolife AB (publ) | 2.08 Billion SEK | 100.0% |
Xvivo Perfusion AB (publ) | 31.43 Million SEK | 100.0% |